Flavonoids as CYP3A4 Inhibitors In Vitro by Martin Kondža, Ivica Brizić, Stela Jokić

Subjects: Get full text

CYP3A4 isoenzyme phenotyping for personalisation of pharmacotherapy by E. A. Egorenkov, V. V. Smirnov, V. N. Kuzina, S. P. Dementiev, G. V. Ramenskaya

Subjects: Get full text

Study on Phenotypical Activity of Isoenzyme CYP3A4 in Children by B. I. Kantemirova, A. KH. Chernysheva, A. K. Starodubtsev, D. A. Sychev

Subjects: Get full text

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs by David Damoiseaux, Wenlong Li, Alejandra Martínez-Chávez, Jos H. Beijnen, Alfred H. Schinkel, Alwin D. R. Huitema, Thomas P. C. Dorlo

Subjects: Get full text

Effect of the Impurities on Drugs, Metabolism, and the Role of the Isoenzyme CYP3A4 by Dreshaj A., Dreshaj A., Veseli D., Sinanaj D., Morina E., Dehari S., Dehari D.

Get full text

Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids by Martin Kondža, Mirza Bojić, Ivona Tomić, Željan Maleš, Valentina Rezić, Ivan Ćavar

Subjects: Get full text

Pengaruh varian gena CYP3A4 terhadap kadar obat by , EM Sutrisna

Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 Interaction by Sean Paul, Brian K. Cooke, Mathew Nguyen

“…In this case, we report a glossopharyngeal dystonia secondary to a lurasidone-fluoxetine CYP-3A4 interaction to highlight the importance of maintaining an index of suspicion for laryngeal dystonia, a potentially fatal dystonia.…”
Get full text

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia by Sh. P. Abdullaev, M. N. Shatokhin, O. L. Sigailo, Sh. P. Abdullaev, P. O. Bochkov, S. N. Tuchkova, O. V. Teodorovich, O. B. Loran, D. A. Sychev

Subjects: Get full text

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4 by Ilia G. Denisov, Yelena V. Grinkova, Mark A. McLean, Tyler Camp, Stephen G. Sligar

Subjects: Get full text

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions by Qihui Kong, Nanyong Gao, Yahui Wang, Guoxin Hu, Jianchang Qian, Bingbing Chen

Subjects: Get full text

CYP3A4 mutation causes vitamin D-dependent rickets type 3 by Roizen, J, Li, D, O'Lear, L, Javaid, M, Shaw, N, Ebeling, P, Nguyen, H, Rodda, C, Thummel, K, Thacher, T, Hakonarson, H, Levine, M

“…In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. …”

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer by Yuting Yang, Yuting Yang, Yanlei Guo, Hua Luo, Menglei Wang, Fang Chen, Huawei Cui, Ping Chen, Zhujun Yin, Li Li, Ying Dai, Jin Zeng, Junning Zhao, Junning Zhao

Subjects: Get full text

African American Women with Cyp3a4/5 Polymorphisms Have Increased Statin Intolerance by Somayya J. Mohammad, Ethan Schwendeman, Patrick S. Dib, Michael W. Milks, Leon McDougle, Philip F. Binkley, Sakima Smith

Get full text

In Silico Dock of TKIs with CYP3A4 and CYP2C8 and Pharmacophore Generation by Ma Zhenya

“…Afatinib, brigatinib, and nilotinib, the three TKIs docked with CYP3A4 and CYP2C8, exhibited more muscular interaction energy with CYP2C8 than with CYP3A4. …”
Get full text

Polymorphism of CYP3A4*1G gene as a predictor of the hepatotoxicity of antituberculosis therapy by H.O. Poludenko, P.B. Antonenko, K.O. Antonenko, O.V. Makarenko

“…The aim of presented research was the investigation of an impact of CYP3A4*1G polymorphism on liver function in patients with TB during anti-tuberculosis therapy. …”
Get full text

Modulation of Nuclear Receptor Action and Regulation of Medicines Biotransformation by S. N. Larina, N. V. Chebyshev, E. V. Shikh

Subjects: Get full text

Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis by David Damoiseaux, Alfred H. Schinkel, Jos H. Beijnen, Alwin D. R. Huitema, Thomas P. C. Dorlo

“…There are several applications of these mouse models regarding in vivo CYP3A4 functionality, one of which might be their capacity to help improve first‐in‐human (FIH) dose predictions for CYP3A4‐metabolized drugs. …”
Get full text

CYP3A4-mediated metabolism of artemisinin to 10β-hydroxyartemisinin with comparable anti-malarial potency by Fanping Zhu, Huixiu Mao, Shanshan Du, Hongchang Zhou, Rui Zhang, Pingli Li, Jie Xing

“…Results A major metabolite 10β-hydroxyartemisinin (ART-M) was found for ART in human, and CYP3A4/3A5 was the major enzymes responsible for ART 10β-hydroxylation. …”
Get full text

How Uremic Toxins Alter Atorvastatin Disposition: Molecular Mechanisms of Inhibition of the Enzyme CYP3A4 by Ashna Asim, Fen Wang, Dong Pu, Sisi Wang, Dian Wang, Wenwen Li, Feng Yu, Li Ji

“…Meanwhile, the protein expression of CYP3A4 was downregulated after incubation with US, IS, and HA (p < 0.01). …”
Get full text